Telix Pharmaceuticals has begun the U.S. commercial rollout of Pixclara, its newly FDA-approved brain cancer imaging agent. The first commercial doses were administered to patients at major hospital networks in Cleveland and Indianapolis, marking the product’s entry into the market.
The launch shows Telix’s ability to bring a product from regulatory approval to clinical use within weeks. Pixclara adds a revenue stream to a portfolio focused primarily on prostate cancer imaging.
Investors will be watching clinician adoption, reimbursement and manufacturing scale-up to assess Pixclara’s financial contribution.